Can stem cells cure CP or guarantee walking?

There is no basis for promising that outcome. Trials assess changes in functional scores in selected participants. Group averages do not predict an individual child’s outcome or demonstrate repair of the injured brain.

Which age and GMFCS level qualify for a cell programme?

There are no universal criteria based on these two measures. A trial’s eligibility limits are not an optimal window for every child. Assessment requires the diagnosis, coexisting conditions and product-specific protocol; participation does not promise benefit.

Should rehabilitation, baclofen or antiseizure medicines be changed?

Do not change prescribed care yourself. Discuss interactions, operations and travel safety with the treating specialists. This website cannot prescribe intervals between a cell intervention, botulinum toxin and surgery, or declare epilepsy compatible with every cell intervention.

HU · HAN'S UNITED · CLINICAL ARCHIVEFOUNDED 2007 · SHANGRAO

Dossier №

001

/ 010

─── Neurology

Stem cells for cerebral palsy in China: research and rehabilitation

Abstract

Stem cells for cerebral palsy in China: research findings, the role of rehabilitation and limitations. Records and cost questions before travelling to Shangrao.

Cell-based interventions for cerebral palsy are being studied in clinical trials. Some findings are encouraging, but they do not justify promising walking, repair of the injured brain or a specific gain in skills for a child. Rehabilitation remains central to care.

Get a consultation All treatments · Neurology

Why individual rehabilitation matters in CP

Care planning focuses on daily needs: movement, communication, eating, comfort and family participation. NICE recommends access to multidisciplinary care and goals agreed with the child and family. Physiotherapy, occupational therapy, communication, nutrition and coexisting conditions may require different specialists. These principles remain relevant whether or not the family considers a cell intervention.

National Institute for Health and Care Excellence · 2017 · NICE guideline NG62

What clinical trials have examined

Small controlled studies of MSCs alongside rehabilitation have reported improvements in some functional measures. The studies differed in product, participant age, regimen and outcome assessment. Cord blood and cord-tissue cells are different interventions. A positive finding from one study does not establish the efficacy of every cell programme for cerebral palsy.

Assessing change without promising an outcome

Before considering a new programme, document current abilities and support needs. Existing GMFCS and GMFM assessments describe baseline function; they are not a test of suitability for cell intervention. Agree goals and repeat assessments with the rehabilitation team. Before-and-after videos or score changes without a controlled comparison cannot separate cell effects from development and rehabilitation.

Safety and the proposed intervention

Small samples and limited follow-up cannot rule out rare or delayed complications. Before consent, obtain product, route, risk and follow-up information. For a trial, request registration and ethics approval. This page does not prescribe intrathecal injections, exosomes or a universal course.

International Society for Stem Cell Research · 2024 · ISSCR patient guide

Preparing a case discussion in Shangrao

Gather existing neurology and rehabilitation reports, operations, current medicines, seizures, feeding needs and assistance required for transfers. Include previous MRI, EEG and functional assessments if available. Do not arrange new tests solely to submit an enquiry; their need is determined by a clinician. The family may also need accessible accommodation, equipment transport and continuity of care.

What the travel estimate should make clear

A fixed course and its cost cannot be determined by a CP diagnosis alone. Request a written proposal separating medical services, investigations, rehabilitation, accommodation, interpretation and assistance. Clarify the length of stay and follow-up costs after returning home. Links below lead to the enquiry process, general prices and contacts; a published price does not establish an indication for a procedure.

Clinical evidence

Studies and clinical guidance

The study designs and limits of their findings are described below. A publication about a cell product does not automatically establish the efficacy of a particular centre’s programme.

Landmark study01

Developmental Medicine & Child Neurology2022

Sun JM, et al. (Duke)

Sun JM, et al. Motor function and safety after allogeneic cord blood and cord tissue-derived mesenchymal stromal cells in cerebral palsy: An open-label, randomized trial. Dev Med Child Neurol. 2022;64(12):1477-1486.

Open-label randomised trial of different products. Confidence intervals for the primary outcome overlapped substantially; the study was not powered for between-group efficacy comparisons. An exploratory analysis suggested a cord-blood signal, not proof for all MSC programmes.

DOI: 10.1111/dmcn.15325

Show 4 more publications

02Stem Cell Research & Therapy2020
Gu J, et al.
Gu J, et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Res Ther. 2020;11:43.
RCT: 40 enrolled, 39 completed assessment. IV hUC-MSCs with rehabilitation improved ADL, CFA and GMFM more than placebo with rehabilitation. The small sample and 12-month follow-up limit conclusions about long-term benefit and risks.
DOI: 10.1186/s13287-019-1545-x
03Cell Transplantation2018
Huang L, Zhang C, Gu J, Wu W, Shen Z, Zhou X, Lu H
Huang L, Zhang C, Gu J, et al. A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. Cell Transplant. 2018;27(2):325-334.
Single-blind placebo-controlled study: 54 children completed follow-up. The authors reported GMFM-88 and CFA improvements with MSCs and rehabilitation. Investigators knew group assignments; the result does not prove brain repair or benefit from every cell product.
DOI: 10.1177/0963689717729379
04NICE guideline NG622017
National Institute for Health and Care Excellence
NICE. Cerebral palsy in under 25s: assessment and management. NICE guideline NG62.
Multidisciplinary CP care: individual goals, communication, nutrition, pain and coexisting conditions. The guideline supports care planning; it does not validate a centre’s cell programme.
Open the publication
05ISSCR patient guide2024
International Society for Stem Cell Research
International Society for Stem Cell Research. The ISSCR Guide to Stem Cell Treatments. February 2024.
Questions about evidence, risks, consent and costs when considering a cell intervention.
Open the publication

This overview of published evidence is for discussion with a clinician. It is not an individual prescription or confirmation of eligibility for a cell intervention.

FAQ

Frequent questions on the diagnosis

01
Autism spectrum disorder
Stem cells for autism in China: research findings, limitations and questions before travelling to Shangrao. What to discuss with a clinician and which records to prepare.

All therapies in Neurology